Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Korea Post-Marketing Surveillance of Invega Sustenna

Trial Profile

Korea Post-Marketing Surveillance of Invega Sustenna

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Jul 2019

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Janssen
  • Most Recent Events

    • 02 Jul 2019 Status changed from recruiting to active, no longer recruiting.
    • 27 Sep 2018 Planned primary completion date changed from 2 Jun 2017 to 1 Jan 2020.
    • 07 May 2018 Planned End Date changed from 4 Mar 2020 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top